Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.69 |
| ▸ | FAAH | O00519 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | CACNA2D1 | P54289 | 8/20 | 0.47 |
| ▸ | CACNB1 | Q02641 | 8/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 7/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.46 |
| ▸ | TACR3 | P29371 | 1/20 | 0.46 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916649 | 0.92 | MGLL (0.58) | MGLLFAAHCACNA2D1CACNB1CACNA1B | |
| SCHEMBL916798 | 0.89 | MGLL (0.55) | MGLLFAAHCNR1CNR2CACNA2D1 | |
| SCHEMBL917630 | 0.82 | MGLL (1.00) | MGLLFAAHKMT2AKDM4EMAPT | |
| SCHEMBL916475 | 0.79 | MGLL (0.81) | MGLLFAAHKDM4ENPSR1CACNA2D1 | |
| SCHEMBL3016226 | 0.76 | HPGD (0.42) | MGLLFAAHKMT2AMAPTHPGD | |
| SCHEMBL13246546 | 0.72 | MGLL (0.81) | MGLLFAAHKMT2AKDM4EMAPT | |
| SCHEMBL916928 | 0.72 | MGLL (0.81) | MGLLFAAHKMT2AKDM4EMAPT | |
| SCHEMBL16598964 | 0.70 | MAOB (0.64) | KMT2AKDM4EHPGDNPSR1ALDH1A1 | |
| SCHEMBL31350838 | 0.70 | MAOB (0.64) | KMT2AKDM4EHPGDNPSR1ALDH1A1 | |
| SCHEMBL3761244 | 0.69 | CACNA2D1 (0.63) | KMT2AKDM4EMAPTHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868007-B2 | Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | claimed |
| EP-2146991-B1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-07-28 | — | — | EP | claimed |
| US-20100035893-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | claimed |
| US-20110071161-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-24 | — | — | US | disclosed |
| US-7868007-B2 | Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | disclosed |
| EP-2146991-B1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-07-28 | — | — | EP | disclosed |
| US-20100035893-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2146991-A2 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008145842-A2 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035893-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | FLT3, QDPR, CYP1A2 | MGLL 3483/4885FAAH 707/4885KMT2A 951/4885 |
| US-20110071161-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | FLT3, QDPR, CYP1A2 | MGLL 3483/4885FAAH 707/4885KMT2A 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.